Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Global Post-Market Clinical Follow-up of the Treovance Stent-Graft for Endovascular Aneurysm Repair: One-Year Results From the RATIONALE Registry

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Commentary: Emergent TAVR During TEVAR

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  1. Commentary on Drug-Eluting Technologies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cutdown Technique is Superior to Fascial Closure for Femoral Artery Access after Elective Endovascular Aortic Repair

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Endovascular aortic repair reduces gluteal oxygenation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Lars Lönn (Medlem af forfattergruppering)
  • RATIONALE Investigators (Lars Lönn, members)
Vis graf over relationer

PURPOSE:: To evaluate the safety and performance of the Treovance stent-graft.

METHODS:: The global, multicenter RATIONALE registry ( ClinicalTrials.gov; identifier NCT03449875) prospectively enrolled 202 patients (mean age 73.0±7.8 years; 187 men) with abdominal aortic aneurysms (AAA) suitable for endovascular aneurysm repair (EVAR) using the Treovance. The composite primary safety endpoint was site-reported all-cause mortality and major morbidity. The primary efficacy outcome was clinical success. Further outcomes evaluated included technical success; stent-graft migration, patency, and integrity; endoleak; and aneurysm size changes.

RESULTS:: Technical success was 96% (194/202); 8 patients had unresolved type I endoleaks at the end of the procedure. There was no 30-day mortality and 1% major morbidity (1 myocardial infarction and 1 bowel ischemia). Clinical success at 1 year was confirmed in 194 (96%) patients; 6 of 8 patients had new/persistent endoleaks and 2 had aneurysm expansion without identified endoleak. A total of 8 (4%) reinterventions were required during the mean 13.7±3.1 months of follow-up (median 12.8). At 1 year, the Kaplan-Meier estimate for freedom from reintervention was 95.6% (95% CI 91.4% to 97.8%). Other estimates were 95.5% (95% CI 91.7% to 97.6%) for freedom from endoleak type I/III and 97.4% (95% CI 94.2% to 98.9%) for freedom from aneurysm expansion. Thirteen (6.4%) patients died; no death was aneurysm related.

CONCLUSION:: The RATIONALE registry showed favorable safety and clinical performance of the Treovance stent-graft for the treatment of infrarenal AAAs in a real-world setting.

OriginalsprogEngelsk
TidsskriftJournal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
Vol/bind25
Udgave nummer6
Sider (fra-til)726-734
Antal sider9
ISSN1526-6028
DOI
StatusUdgivet - dec. 2018

ID: 55695420